Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LGALS3 | P17931 | 3/20 | 0.53 |
| ▸ | LGALS8 | O00214 | 2/20 | 0.53 |
| ▸ | LGALS4 | P56470 | 2/20 | 0.53 |
| ▸ | LGALS9 | O00182 | 1/20 | 0.48 |
| ▸ | LGALS1 | P09382 | 1/20 | 0.48 |
| ▸ | LGALS7; LGALS7B | P47929 | 1/20 | 0.48 |
| ▸ | IGF2R | P11717 | 2/20 | 0.48 |
| ▸ | MEN1 | O00255 | 1/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.48 |
| ▸ | AMY1A | P0DUB6 | 1/20 | 0.47 |
| ▸ | TYR | P14679 | 6/20 | 0.45 |
| ▸ | CD69 | Q07108 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5544380 | 1.00 | LGALS3 (0.53) | LGALS3LGALS8LGALS4LGALS9LGALS1 | |
| SCHEMBL16715894 | 0.91 | LGALS3 (0.45) | LGALS3LGALS8LGALS4LGALS9LGALS1 | |
| SCHEMBL7521033 | 0.90 | AMY1A (0.43) | LGALS3LGALS8LGALS4LGALS9LGALS1 | |
| SCHEMBL229613 | 0.89 | SLC28A3 (0.50) | LGALS8TYRCD69 | |
| SCHEMBL22026379 | 0.89 | SLC28A3 (0.50) | LGALS8TYRCD69 | |
| SCHEMBL4703623 | 0.89 | SLC28A3 (0.50) | LGALS8TYRCD69 | |
| SCHEMBL19603336 | 0.89 | SLC28A3 (0.50) | LGALS8TYRCD69 | |
| SCHEMBL3144972 | 0.89 | SLC28A3 (0.50) | LGALS8TYRCD69 | |
| SCHEMBL22047951 | 0.89 | SLC28A3 (0.50) | LGALS8TYRCD69 | |
| SCHEMBL16285372 | 0.89 | SLC28A3 (0.50) | LGALS8TYRCD69 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-104471071-B | Sugar esters as inducers of gene expression | 青岛蔚蓝生物集团有限公司 | 2021-05-28 | — | — | CN | disclosed |
| US-20210079438-A1 | CARBOHYDRATE ESTERS AS INDUCERS FOR GENE EXPRESSION | QINGDAO VLAND BIOTECH GROUP CO LTD (CN) | 2021-03-18 | — | — | US | disclosed |
| US-10870873-B2 | Method of using carbohydrate esters as inducers for gene expression | QINGDAO VIAND BIOTECH GROUP CO., LTD. (CN) | 2020-12-22 | — | — | US | disclosed |
| CN-107012188-B | Preparation method of gene expression inducer | 青岛蔚蓝生物集团有限公司 | 2020-10-30 | — | — | CN | disclosed |
| CN-106977558-B | Method for producing sophorose ester compound | 青岛蔚蓝生物集团有限公司 | 2020-06-09 | — | — | CN | disclosed |
| CN-107011391-B | Method for producing sophorose | 青岛蔚蓝生物集团有限公司 | 2020-05-22 | — | — | CN | disclosed |
| US-20180327804-A1 | CARBOHYDRATE ESTERS AS INDUCERS FOR GENE EXPRESSION | QINGDAO VLAND BIOTECH GROUP CO., LTD. (CN) | 2018-11-15 | — | — | US | disclosed |
| US-10059973-B2 | Carbohydrate esters as inducers for gene expression | QINGDAO VLAND BIOTECH GROUP CO., LTD. (CN) | 2018-08-28 | — | — | US | disclosed |
| US-20150152462-A1 | Carbohydrate Esters as Inducers for Gene Expression | SOPHORO BIOTECHNOLOGIES, LLC (US) | 2015-06-04 | — | — | US | disclosed |
| CN-104666318-A | Novel sulfated oligosaccharide derivatives | PROGEN PHARMACEUTICALS LTD | 2015-06-03 | — | — | CN | disclosed |
| EP-2875143-A1 | CARBOHYDRATE ESTERS AS INDUCERS FOR GENE EXPRESSION | Sophoro Biotechnologies LLC (US) | 2015-05-27 | — | — | EP | disclosed |
| WO-2014015179-A1 | CARBOHYDRATE ESTERS AS INDUCERS FOR GENE EXPRESSION | SOPHORO BIOTECHNOLOGIES, LLC (US) | 2014-01-23 | — | — | WO | disclosed |
| US-20080207532-A1 | Use of Nordihydroguaiaretic Acid Derivatives in the Treatment of Drug Resistant Cancer, Viral and Microbial Infection | JOHNS HOPKINS UNIVERSITY (US) | 2008-08-28 | — | — | US | disclosed |
| EP-1848418-A2 | USE OF NORDIHYDROGUAIARETIC ACID DERIVATIVES IN THE TREATMENT OF DRUG RESISTANT CANCER, VIRAL AND MICROBIAL INFECTION | Johns Hopkins University (US) | 2007-10-31 | — | — | EP | disclosed |
| WO-2006041902-A2 | USE OF NORDIHYDROGUAIARETIC ACID DERIVATIVES IN THE TREATMENT OF DRUG RESISTANT CANCER, VIRAL AND MICROBIAL INFECTION | JOHNS HOPKINS UNIVERSITY (US) | 2006-04-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10870873-B2 | Method of using carbohydrate esters as inducers for gene expression | MGAM, HSD17B14, ERG28 | LGALS3 818/4885LGALS8 689/4885LGALS4 454/4885 |
| US-20180327804-A1 | CARBOHYDRATE ESTERS AS INDUCERS FOR GENE EXPRESSION | HSD17B14, MGAM, ATF4 | LGALS3 738/4885LGALS8 583/4885LGALS4 382/4885 |
| US-20080207532-A1 | Use of Nordihydroguaiaretic Acid Derivatives in the Treatment of Drug Resistant Cancer, Viral and Microbial Infection | ABCC1, ABCB1, HPGD | LGALS3 2065/4885LGALS8 2947/4885LGALS4 2715/4885 |
| US-10059973-B2 | Carbohydrate esters as inducers for gene expression | HSD17B14, MGAM, ATF4 | LGALS3 738/4885LGALS8 583/4885LGALS4 382/4885 |
| US-20150152462-A1 | Carbohydrate Esters as Inducers for Gene Expression | HSD17B14, MGAM, ATF4 | LGALS3 738/4885LGALS8 583/4885LGALS4 382/4885 |
| US-20210079438-A1 | CARBOHYDRATE ESTERS AS INDUCERS FOR GENE EXPRESSION | HSD17B14, MGAM, ATF4 | LGALS3 738/4885LGALS8 583/4885LGALS4 382/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.